Skip to main content
Year archive

Xlife Sciences AG — 2020 filings

All 22 regulatory filings released by Xlife Sciences AG (XLS) in 2020, sourced directly from the official regulator.

22 Filings
2020 Period
2020 filings (22)
Filing Released Lang
Xlife Sciences AG: Exit of a project company
Regulatory Filings
2020-12-23 English
Xlife Sciences AG: Successful capital raising of six million Swiss francs
Share Issue/Capital Change
2020-12-04 English
Xlife Sciences AG: Xlife Sciences expands its project portfolio
Regulatory Filings
2020-12-03 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing
2020-11-05 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing
2020-11-05 English
M.M. Warburg sets price target to EUR 55.75
Earnings Release FY 2020
2020-11-02 English
Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75 (news with additional features)
Earnings Release FY 2020
2020-11-02 English
Xlife Sciences AG: M.M. Warburg setzt Kursziel auf EUR 55.75
Regulatory Filings
2020-10-28 German
Xlife Sciences AG: Xlife Sciences takes stake in palleos healthcare
M&A Activity
2020-08-05 English
Xlife Sciences AG: New project company x-nuclear diagnostic GmbH acquires new proprietary technology in nuclear medical diagnostics
Regulatory Filings
2020-07-23 English
Xlife Sciences AG: Project company inflamed pharma GmbH obtains grant for COVID-19 project covering 70% of funding
Regulatory Filings
2020-07-02 English
Xlife Sciences AG: Xlife Sciences waives early redemption of the privately placed convertible bond until July 1, 2023
Capital/Financing Update
2020-07-01 English
Xlife Sciences shares traded on XETRA
Delisting Announcement
2020-07-01 English
Xlife Sciences AG: Xlife Sciences shares traded on XETRA
Delisting Announcement
2020-07-01 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing
2020-06-11 English
Xlife Sciences AG: The project company FUSE-AI GmbH reaches another milestone by developing ProstateCarcinoma.ai
Environmental & Social Information
2020-06-10 English
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)
Regulatory Filings
2020-03-11 English
Xlife Sciences AG: Capital Increase 'Private Placement'
Capital/Financing Update
2020-02-14 English
Xlife Sciences AG: New project in the portfolio
Regulatory Filings
2020-01-24 English
DGAP-DD: Xlife Sciences AG english
Director's Dealing
2020-01-17 English
Xlife Sciences AG: Neues Projekt im Portfolio
Regulatory Filings
2020-01-17 German
Xlife Sciences AG: Velabs Therapeutics receives exclusive licence from alytas therapeutics for the development of therapeutic antibodies as senolytics
Regulatory Filings
2020-01-07 English